Castration Resistant Prostate Cancer Treatment - AC225 PSMA Therapy(Targeted Alpha Therapy)
In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with Ac225 PSMA Therapy (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidence of a significant Radiological and Biochemical Response with prolonged duration of response. ADVERSE EFFECTS: The Ac225 PSMA Therapy is extremely well tolerated with minimal adverse effects that usually do not require any active management. The adverse effects usually experienced are fatigue in the immediate post-therapy, a transient mild drop in blood counts approximately three-weeks post-therapy and dry mouth. SOURCING OF Ac 225: The Ac225 used at the center is a highly purified form with no added carriers. It is approved by the European Medicines Associ...